PT - JOURNAL ARTICLE AU - Chantal B.F. Vogels AU - Mallery Breban AU - Tara Alpert AU - Mary E. Petrone AU - Anne E. Watkins AU - Emma B. Hodcroft AU - Christopher E. Mason AU - Gaurav Khullar AU - Jessica Metti AU - Joel T. Dudley AU - Matthew J. MacKay AU - Megan Nash AU - Jianhui Wang AU - Chen Liu AU - Pei Hui AU - Steven Murphy AU - Caleb Neal AU - Eva Laszlo AU - Marie L. Landry AU - Anthony Muyombwe AU - Randy Downing AU - Jafar Razeq AU - Richard A. Neher AU - Joseph R. Fauver AU - Nathan D. Grubaugh TI - PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern AID - 10.1101/2021.01.28.21250486 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.28.21250486 4099 - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21250486.short 4100 - http://medrxiv.org/content/early/2021/02/01/2021.01.28.21250486.full AB - With the emergence of SARS-CoV-2 variants that may increase transmissibility and/or cause escape from immune responses1–3, there is an urgent need for the targeted surveillance of circulating lineages. It was found that the B.1.1.7 (also 501Y.V1) variant first detected in the UK4,5 could be serendipitously detected by the ThermoFisher TaqPath COVID-19 PCR assay because a key deletion in these viruses, spike Δ69-70, would cause a “spike gene target failure” (SGTF) result. However, a SGTF result is not definitive for B.1.1.7, and this assay cannot detect other variants of concern that lack spike Δ69-70, such as B.1.351 (also 501Y.V2) detected in South Africa6 and P.1 (also 501Y.V3) recently detected in Brazil7. We identified a deletion in the ORF1a gene (ORF1a Δ3675-3677) in all three variants, which has not yet been widely detected in other SARS-CoV-2 lineages. Using ORF1a Δ3675-3677 as the primary target and spike Δ69-70 to differentiate, we designed and validated an open source PCR assay to detect SARS-CoV-2 variants of concern8. Our assay can be rapidly deployed in laboratories around the world to enhance surveillance for the local emergence spread of B.1.1.7, B.1.351, and P.1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by CTSA Grant Number TL1 TR001864 (TA and MEP), Fast Grant from Emergent Ventures at the Mercatus Center at George Mason University (NDG), and CDC Contract # 75D30120C09570 (NDG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board from the Yale University Human Research Protection Program determined that the RT-qPCR testing and sequencing of de-identified remnant COVID-19 clinical samples conducted in this study is not research involving human subjects (IRB Protocol ID: 2000028599). The 'Yale ID' numbers displayed in Table 2 are not known outside the research group and cannot be used to re-identify any subject. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data are available on GISAID (see Table 2 for accession numbers). All RT-qPCR data are included in this article, supplementary files, and source data. https://www.gisaid.org/